Twist Bioscience (TWST) to Release Quarterly Earnings on Monday

Twist Bioscience (NASDAQ:TWST) is scheduled to issue its quarterly earnings data before the market opens on Monday, November 18th. Analysts expect the company to announce earnings of ($0.73) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $45.40 on Monday. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -11.88 and a beta of 1.78. Twist Bioscience has a fifty-two week low of $15.85 and a fifty-two week high of $60.90. The stock’s fifty day moving average is $43.69 and its two-hundred day moving average is $45.74.

Analyst Upgrades and Downgrades

TWST has been the subject of several recent research reports. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird lifted their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Leerink Partners increased their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Barclays reduced their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Finally, JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $51.22.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 856 shares of the company’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the transaction, the chief financial officer now owns 73,397 shares of the company’s stock, valued at $3,068,728.57. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Emily M. Leproust sold 14,334 shares of Twist Bioscience stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $639,296.40. Following the transaction, the chief executive officer now owns 589,552 shares in the company, valued at approximately $26,294,019.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam Laponis sold 856 shares of the company’s stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total value of $35,789.36. Following the sale, the chief financial officer now owns 73,397 shares of the company’s stock, valued at $3,068,728.57. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 73,356 shares of company stock valued at $3,205,239. Insiders own 3.92% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.